DEFIBROTIDE FOR THE TREATMENT OF VENO-OCCLUSIVE DISEASE AFTER LIVER TRANSPLANTATION
- 1 October 2001
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 72 (7), 1237-1240
- https://doi.org/10.1097/00007890-200110150-00009
Abstract
Veno-occlusive disease (VOD) after liver transplantation is associated with acute rejection and poor outcome. The use of antithrombotic and thrombolytic agents is limited by their toxicity. Defibrotide is a polydeoxyribonucleotide with thrombolytic and antithrombotic properties and no systemic anticoagulant effect. Defibrotide, 35–40 mg/kg/day, was administered intravenously for 21 days on a compassionate-use basis to two patients aged 66 and 49 years. VOD had developed 6 weeks and 4 months after orthotopic liver transplantation for hepatitis C and hepatitis B infection, respectively. VOD was diagnosed clinically by findings of weight gain (8.5% and 16%), ascites, jaundice (serum bilirubin 5.4 mg/dl and 21.7 mg/dl), and severe coagulopathy (in one patient), and histologically by the presence of hemorrhagic centrilobular necrosis and fibrous stenosis of the hepatic venules. One of the patients had received azathioprine as part of the immunosuppressive regimen. There was no evidence of acute cellular rejection histologically. After 3 weeks of defibrotide administration, the first patient showed complete clinical resolution of the VOD, and serum bilirubin level normalized. He is alive 6 months after transplantation. The second patient, treated at a later stage of disease, showed marked improvement in the coagulopathic state, but there was no resolution of the VOD. He died 2 months later of multiorgan failure due to Escherichia coli sepsis. Neither patient had side effects from the drug. Defibrotide is a promising drug for the treatment of VOD after liver transplantation and needs to be evaluated in large, prospective studies.Keywords
This publication has 16 references indexed in Scilit:
- “Silent” presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilectionHepatology, 1999
- Treatment of Hepatic Venocclusive Disease With Recombinant Human Tissue Plasminogen Activator and Heparin in 42 Marrow Transplant PatientsBlood, 1997
- Isolation and Identification of Aptamers from Defibrotide That Act as Thrombin Antagonists in VitroBiochemical and Biophysical Research Communications, 1994
- Hepatic venular stenosis after orthotopic liver transplantationHepatology, 1994
- DefibrotideDrugs, 1993
- Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantationBlood, 1992
- Azathioprine hepatotoxicity after liver transplantationHepatology, 1991
- Hepatic veno-occlusive diseaseAmerican Journal Of Medicine, 1986
- Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing FactorsHepatology, 1984
- AN EPIDEMIC OF VENO-OCCLUSIVE DISEASE OF LIVER IN CENTRAL INDIAThe Lancet, 1976